Will Cel-Sci get FDA approval?
Will Cel-Sci get FDA approval?
The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval….
| NEWS RELEASE | |
|---|---|
| 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com | COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 |
What does Cel-Sci do?
CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. Use your immune system to fight disease.
Who owns CEL-SCI?
Top 10 Owners of CEL-SCI Corp
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 4.56% | 1,974,351 |
| SSgA Funds Management, Inc. | 2.27% | 980,339 |
| Renaissance Technologies LLC | 1.79% | 772,883 |
| Geode Capital Management LLC | 1.59% | 689,740 |
Where is Cel-Sci located?
Vienna, Virginia
Cel-Sci Corporation
| Type | Public |
|---|---|
| Headquarters | Vienna, Virginia , United States |
| Key people | Geert Kersten, CEO |
| Products | Multikine, LEAPS, HGP-30 |
| Revenue | US$559,000 (2020) |
Is CEL SCI a good buy?
CEL-SCI Corp (NYSE American:CVM) The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +366.39% increase from the last price of 3.65.
Why did Cel Sci stock drop?
The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
Will multikine get FDA approval?
Multikine has not been licensed or approved by the FDA or by any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
Will Cel Sci stock go up?
The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +461.98% increase from the last price of 3.03.
Why is Cel Sci stock dropping?
How does multikine work?
Multikine is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body’s immune system prior to SOC to attack the cancer.
Is CEL SCI a good stock to buy?
The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +464.78% increase from the last price of 3.01.
Will Cel-Sci stock go up?
